Collaborative Engagement in Clinical Trial Design
A Quality‑by‑Design Approach to Collaborative Trial Design
Designing high‑quality clinical trials is increasingly complex. Sponsors must deliver studies that are scientifically rigorous, operationally executable, ethically sound, and capable of generating evidence that supports regulatory approval, real‑world use, and patient access. Achieving all of this requires more than technical excellence—it requires intentional collaboration across the clinical trial ecosystem.
The Collaborative Engagement in Clinical Trial Design Roadmap was developed to help navigate this complexity by providing practical, phase‑specific guidance on engaging key collaborators throughout the trial design process. These collaborators—including patients and caregivers, investigators and site staff, regulatory agencies, institutional review boards (IRBs), technology and data partners, and payers—bring distinct perspectives that strengthen study design, surface risks earlier, and improve the likelihood of successful trial execution.
At its core, this roadmap is grounded in Quality by Design (QbD). QbD emphasizes identifying what is truly critical to quality and proactively designing trials to reliably deliver meaningful outcomes. While QbD principles are well established, Sponsors often lack clear guidance on when to engage different collaborator groups, why their input matters at specific stages, and how to incorporate that input in a practical and efficient way. This roadmap addresses that need.
Bringing Quality by Design to Life
Quality by Design is most effective when trial designs are intentionally “pressure‑tested” through multiple perspectives. Different collaborators surface different types of risks—and that diversity of insight is a strength of the process.
- Sponsors and CROs often identify systemic and design‑level risks, such as vulnerabilities that could affect study validity, endpoint interpretability, or data integrity.
- Clinical sites provide essential insight into operational feasibility—how protocols function within real clinic workflows, patient populations, and resource constraints.
- Patients and clinical experts highlight feasibility, burden, and ethical considerations that influence enrollment, retention, and overall trial experience.
By encouraging open dialogue and critical thinking across these perspectives, trial teams can identify “paper versus practice” gaps early, simplify overly complex designs, and focus resources on what truly matters.
A QbD‑driven, collaborative approach also promotes leaner, more purposeful trials. Every procedure, assessment, and data point should serve a clear objective related to participant safety or meaningful endpoints. Eliminating non‑essential complexity reduces burden, minimizes opportunities for error, and supports data credibility.
How to Use This Roadmap
This roadmap is designed to support clinical trial designers, Sponsors, and program teams as they move from study concept through final protocol development. For each stage of trial design, it explains:
- Why engaging specific collaborator groups matters at that point
- What types of insights those collaborators can provide
- How Sponsors can engage them effectively using practical strategies
By aligning collaborative engagement with Quality by Design principles, the Roadmap helps teams design trials that are not only scientifically sound, but also feasible to conduct, meaningful to participants, responsive to regulatory and payer expectations, and positioned to deliver real‑world impact.
Patient and Caregivers
Patients are people affected by the disease being studied. Caregivers are anyone providing patients with support and care. As these groups are directly affected by the quality, efficiency, and accessibility of trials, they are primary collaborators in trial design and implementation. Engagement of patients and caregivers leads to more meaningful clinical trials with increased feasibility, enhanced recruitment and retention, and real-world outcomes.
Investigator and Site
Principal Investigators are the researcher(s) charged with conducting a trial. Their responsibilites include overseeing study conduct, delegating study activities to qualified professionals (e.g., analyzing data), and performing study-specific tests and procedures. Many clinical trials are performed across multiple research sites. Day-to-day study activities are performed by trained site staff. Engagement of these groups promotes partnership and feeds clear communication during trial planning and execution.
Regulator
Regulatory agencies (e.g., U.S. Food & Drug Administration, European Medicines Agency) are responsible for reviewing clinical trial plans and outcomes to ensure participants are protected from excessive risk, data is robust and secure, and evidence is sufficient to support market use of the investigational medical product. Engagement of this group in trial design helps to ensure all clinical trials are accurately designed, conducted, analyzed, and reported.
IRB
Institutional Review Boards (IRBs) are diverse committees of experts, patients, and other collaborators who review clinical trials to ensure they comply with federal and state regulations, meet ethical standards, follow institutional policies, and protect the rights and welfare of human research subjects
Tech, Device, and Data Co.
Biotechnology, device, and data vendors are the companies providing the tools needed to monitor participants, fufill study endpoints, and collect, store, and analyze trial data. Early engagement of this group facilitates seamless and effective incorporation of technology into trials.
Payer
Payers are health plan providers/insurers who typically finance health services for patients, which includes non-investigational tests and procedures that occur during participation in a clinical trial. Involvement of payers in trial planning aids in producing robust data that is applicable to the payer's business and concerns.
Collaborator Engagement
It is important to note that while the focus of this specific roadmap is on the process of designing a clinical trial -- from concept to final protocol -- collaborator engagement in drug development must start much earlier than the protocol-writing stage. To make a truly meaningful impact Sponsors must engage with diverse collaborators as early as possible to ensure they have a strong understanding of the current treatment landscape, physician behaviors and preferences, outcomes and benefits patients desire in their care, as well as the gaps their new medicine will address. Early and systematic engagement is a cornerstone of purposeful drug development. As a result, the Collaborative Engagement in Clinical Trial Design includes background documents that outline various stages at which collaborator input should be sought prior to protocol writing. Sponsors should consult these documents to develop a robust engagement strategy for their drug development programs and associated clinical trials. While each study may be unique in some ways and is fit for purpose, all studies should share in the early and often engagement of diverse collaborator groups and be written and edited with a quality approach.
Quality Engagement of All
Collaborator Groups
Trial Design Phase
While there are specific engagements that would occur as a result of the given disease area of interest or stage of medical product development (early, mid, late), this guide focuses on engagements that should occur during the protocol development stage (synopsis, study concept, draft protocol, final protocol).
Study Concept*
Pre-initiation, high-level description of the purpose and approach to addressing a clinical question; a paragraph that addresses, at minimum, the populations being studied, the central research question, and the research gap the study is meant to fill
Synopsis*
Pre-initiation, brief summary of study plan that is more detailed than the study concept but less detailed than the protocol; a 2-3 page description of the study's major activities, including the study concept, background, and supportive preliminary data
Draft Protocol
Pre-initiation document specifying the study plan (including the background/rationale, inclusion/exclusion criteria, endpoint definitions, the visit/treatment schedule, statistical analysis plan, etc.); a protocol that is fairly complete but not yet finalized and approved
Final Protocol
Pre-initiation document specifying the study plan (including the background/rationale, inclusion/exclusion criteria, endpoint definitions, the visit/treatment schedule, statistical analysis plan, etc.) that has ideally been refined after receiving multi-collaborator input; a protocol that is fully approved by study governance and IRB
*While not all organizations differentiate between the study concept and synopsis, for those that do, the goal of the synopsis is to think through the same information from study concept in greater detail involving each applicable collaborator.